Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | STS | P08842 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11857394 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL11857389 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL28068491 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL11862021 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL11853537 | 0.90 | LMNA (0.71) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL8900956 | 0.89 | LMNA (0.69) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL7177976 | 0.88 | STS (0.74) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| Methoxymethane SCHEMBL11237362 | 0.87 | HSD17B1 (0.70) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL7186839 | 0.85 | HSD17B1 (0.74) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL14946871 | 0.85 | HSD17B1 (0.65) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365768-B1 | USE OF ER-BETA SELECTIVE ANTAGONISTS AS CONTRACEPTIVES | BAYER SCHERING PHARMA AG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6794409-B2 | HOMOSTEROIDS SUCH AS 17-CHLORO-17A-ALPHA-ETHINYL-17A, 18A-DIHOMO-ESTRA-1,3,5(10),16-TETRAENE-3,17A BETA-DIOL; WITHOUT USE OF PROGESTIN; CONTRACEPTION; FOR TREATMENT OF PROLIFERATIVE DISEASES OF THE OVARY | SCHERING AG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1365768-A2 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | Schering Aktiengesellschaft (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2002068548-A9 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | SCHERING AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002068548-A1 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | SCHERING AG (DE) | 2002-09-06 | — | — | WO | disclosed |
| EP-0815120-B1 | 17-DIFLUOROMETHYLENE-OESTRATRIENES | SCHERING AG (DE) | 2001-02-14 | — | — | EP | disclosed |
| US-6136800-A | STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-24 | — | — | US | disclosed |
| US-6018062-A | SUCH AS 17-DIFLUOROMETHYLENE-ESTRA-1,3,5(10)-TRIEN-3-OL; USE AS ANTIOXIDANTS AND VASCULOPROTECTIVE AGENTS AS THEY CAUSE VASODILATOR NITROGEN OXIDE RELEASE AND PREVENT OXIDATION OF LDL CHOLESTEROL | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-25 | — | — | US | disclosed |
| EP-0285548-A1 | Process for the preparation of 17-alpha-ethynyl-17-beta-hydroxy-18-methyl-4,15-estradien-3-one, and intermediates for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-10-05 | — | — | EP | disclosed |
| US-4333928-A | PROGESTATIONAL ACTIVITY | SCHERING, AKTIENGESELLSCHAFT (DE) | 1982-06-08 | — | — | US | disclosed |
| EP-0019247-B1 | 16-ALPHA-ALKYL STEROIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-11-25 | — | — | EP | disclosed |
| EP-0019247-A1 | 16-Alpha-alkyl steroids, process for their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-11-26 | — | — | EP | disclosed |
| US-4118488-A | 4-Androsten-3-ones and process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4016269-A | 17α-HYDROXY-1,3,5(10),15-ESTRATETRAENES AND PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3984476-A | CONTRACEPTIVES AND MENSTRUAL CYCLE REGULATORS | FURST ANDOR | 1976-10-05 | — | — | US | disclosed |
| US-3971809-A | 3A,4,7,7A-Tetrahydro-4-phenylethyl-7a-alkyl-5(6H)-indanones and process for the preparation thereof | HOFFMANN-LA ROCHE INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | disclosed |
| US-3933870-A | Synthesis of A-ring aromatic steroids | HOFFMANN-LA ROCHE INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESRRB, ESR2 | LMNA 4408/4885HSD17B1 280/4885MAPT 4773/4885 |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESR2, ESRRB | LMNA 4313/4885HSD17B1 261/4885MAPT 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.